A GLP-1 receptor agonist is a molecule that binds and activates the GLP-1 receptor, reproducing the signalling of native GLP-1 but with engineered resistance to enzymatic breakdown. The class exists because the native hormone lasts about two minutes in plasma.
Two structural families
Human GLP-1 analogs — liraglutide and semaglutide — keep the human backbone and add protection: an Aib substitution at position 8 to block DPP-4, and a fatty-acid chain attached through a linker at position 26 to drive reversible albumin binding. Exendin-based agonists take a different route, using the exendin-4 sequence from Gila monster venom, which is naturally DPP-4 resistant because of its glycine at position 2.
How they differ in practice
The variables that matter when selecting a reference standard are receptor potency, plasma half-life, and whether the molecule engages other receptors. Liraglutide's acylation supports roughly daily duration; semaglutide's C18 diacid and additional substitution extend it to weekly. Multi-receptor molecules such as dual and triple agonists retain a GLP-1 arm but are not classified simply as GLP-1 receptor agonists.
Related terms
incretin. Browse GLP-1 and incretin peptides, or compare Semaglutide and Liraglutide in this research comparison.